Regeneron Pharmaceuticals, Inc. (REGN)

Nasdaq · Healthcare · Biotechnology
$920.69-0.19%As of 2026-11-22 · USD
Last session low $916.66Last session high $948.42
52-week low $591.5252-week high $991.73
Market cap
$95.24B
Sector
Healthcare
P/E (TTM)
20.4x
Dividend yield
0.41%
Next earnings
2027-01-28 (est.)

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)57.9In the neutral range (30 to 70)
MACD (12, 26, 9)33.73Below its signal line (37.99); histogram -4.27
Bollinger %B (20, 2)54%Inside the bands (806.92 to 1,019.13)
SMA 20913.02Price is 0.8% above
SMA 50829.81Price is 11.0% above
SMA 200751.34Price is 22.5% above
ATR (20)3.12% of priceAverage true range per day
52-week position82%In the upper part of the 591.52 to 991.73 range

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.

Insider filings, 90 daysNo purchases and 16 sales (about $59.2M).
Latest fiscal yearEnded 2025-12-31: revenue of $14.34B and an operating margin of 25.8%.
Next earnings reportExpected on 2027-01-28 (the date is an estimate).

More in Biotechnology